Mercury Biopharmaceutical (ROCO:6932) Cash-to-Debt : 6.31 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Mercury Biopharmaceutical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Mercury Biopharmaceutical's cash to debt ratio for the quarter that ended in Jun. 2024 was 6.31.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Mercury Biopharmaceutical could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Mercury Biopharmaceutical's Cash-to-Debt or its related term are showing as below:

ROCO:6932' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.27 Med: 7.04 Max: No Debt
Current: 6.31

During the past 5 years, Mercury Biopharmaceutical's highest Cash to Debt Ratio was No Debt. The lowest was 1.27. And the median was 7.04.

ROCO:6932's Cash-to-Debt is ranked better than
72.83% of 1016 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs ROCO:6932: 6.31

Mercury Biopharmaceutical Cash-to-Debt Historical Data

The historical data trend for Mercury Biopharmaceutical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Mercury Biopharmaceutical Cash-to-Debt Chart

Mercury Biopharmaceutical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

1.27

3.24

7.77

Mercury Biopharmaceutical Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial				2.58	3.24	8.31	7.77	6.31

Competitive Comparison of Mercury Biopharmaceutical's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mercury Biopharmaceutical's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Mercury Biopharmaceutical's Cash-to-Debt falls into.

Mercury Biopharmaceutical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Mercury Biopharmaceutical's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	329.074	/	(0.681	+	41.668)
	=	7.77

Mercury Biopharmaceutical's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	264.893	/	(0.446	+	41.508)
	=	6.31

Mercury Biopharmaceutical (ROCO:6932) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Mercury Biopharmaceutical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Mercury Biopharmaceutical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Mercury Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mercury Biopharmaceutical Corp (ROCO:6932) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 653-1, Bannan Road, 15th Floor, Zhonghe District, New Taipei City, TWN

Website

https://www.merdury.com.tw

Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.

Mercury Biopharmaceutical Headlines

No Headlines